Corvus Pharmaceuticals (CRVS) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 45.9% versus a gain of 16.3%. Over five years, CRVS leads with a +106.3% price change compared with +6.7% for MLTX. MoonLake Immunotherapeutics is the larger company by market cap ($900.4 million vs $858.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | MLTX |
|---|---|---|
| Share price | $10.21 | $10.58 |
| Market cap | $858.87M | $900.43M |
| 1-day change | -1.92% | -1.76% |
| YTD return | +32.60% | -19.73% |
| 1-year return | +45.86% | +16.26% |
| 5-year return | +106.26% | +6.65% |
| EPS (TTM) | $-0.62 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $23.29 |
| 52-week low | $6.39 | $8.80 |
| Distance from 52-week high | -62.12% | -54.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +224.58% | +169.75% |
| Average volume | 986.04K | 1.47M |
| Shares outstanding | 84.12M | 85.11M |
| Employees | 37 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed MLTX by 29.6 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
CRVS vs MLTX FAQ
Which is bigger, Corvus Pharmaceuticals or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $900.43M compared with $858.87M for Corvus Pharmaceuticals (CRVS).
Which stock has performed better over the past year, CRVS or MLTX?
CRVS returned +45.86% over the past 12 months, compared with +16.26% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.